{{Infobox drug
| drug_name         =
| INN               =
| type              =<!-- empty -->
| IUPAC_name        =  ''N'''-{5-[Acetyl(hydroxy)amino]pentyl}-''N''-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-''N''-hydroxysuccinamide
| image             = Deferoxamine-2D-skeletal.png
| width             = 
| alt               = 
| image2            = Deferoxamine-3D-vdW.png
| width2            = 
| alt2              = 
| imageL            =
| widthL            =
| altL              = 
| imageR            = 
| widthR            = 
| altR              = 
| caption           = Skeletal formula and spacefill model of deferoxamine
<!-- Clinical data -->
| pronounce         =
| tradename         = Desferal
| Drugs.com         = {{drugs.com|monograph|deferoxamine-mesylate}}
| MedlinePlus       = 
| licence_EU        = <!-- EMA requires brand name -->
| licence_US        = <!-- FDA may use generic name -->
| DailyMedID        = <!-- preference to licence_US -->
| pregnancy_AU      = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU_comment =      
| pregnancy_US      = C
| pregnancy_US_comment = 
| pregnancy_category= 
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = {{unbulleted list|intramuscular|intravenous|subcutaneous}}
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment = 
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment = 
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment = 
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US_comment = 
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment = 
| legal_status      = <!--For countries not listed above-->
<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       =
| onset             = 
| elimination_half-life = 6 hours
| duration_of_action =
| excretion         =
<!-- Identifiers -->
| CAS_number        = 70-51-9
| CAS_supplemental  = {{cascite|correct|CAS}}
| ATCvet            = 
| ATC_prefix        = V03
| ATC_suffix        = AC01
| ATC_supplemental  = 
| PubChem           = 2973
| PubChemSubstance  = 
| IUPHAR_ligand     = 
| DrugBank          = DB00746
| ChemSpiderID      = 2867
| UNII              = J06Y7MXW4D
| KEGG              = D03670
| ChEBI             =  4356
| ChEMBL            = 556
| NIAID_ChemDB      =
| synonyms          = desferrioxamine B, desferoxamine B, DFO-B, DFB ,N'-[5-(Acetyl-hydroxy-amino)pentyl]-N-[5-[3-(5-aminopentyl-hydroxy-carbamoyl) propanoylamino]pentyl]-N-hydroxy-butane diamide
<!-- Chemical data -->
| chemical_formula  = 
| C=25 | H=48 | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I=
| K= | Li= | Mg= | Mn= | N=6 | Na= | O=8 | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge=
| molecular_weight  = 
| SMILES            =  Cc(:[o]):n(:[oH])CCCCC[nH]:c(:[o])CCc(:[o]):n(:[oH])CCCCC[nH]:c(:[o])CCc(:[o]):n(:[oH])CCCCCN
| Jmol              = 
| StdInChI          = 1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)
| StdInChI_comment  =  {{stdinchicite|correct|chemspider}}
| StdInChIKey       = UBQYURCVBFRUQT-UHFFFAOYSA-N
| density           = 
| density_notes     = 
| melting_point     = 
| melting_high      = 
| melting_notes     = 
| boiling_point     = 
| boiling_notes     = 
| solubility        = 
| specific_rotation = 
}}
<!-- Definition and medical uses -->
'''Deferoxamine''' ('''DFOA'''), sold under the brand name '''Desferal''', is a medication that binds [[iron]] and [[aluminium]].<ref name=AHFS2016/> It is specifically used in [[iron overdose]], [[hemochromatosis]] either due to multiple [[blood transfusion]]s or an underlying [[genetic condition]], and [[aluminium toxicity]] in people on [[dialysis]].<ref name=AHFS2016/><ref name=WHO2008>{{cite book|title=WHO Model Formulary 2008|date=2009|publisher=World Health Organization|isbn=978-92-4-154765-9|pages=61–62|url=http://apps.who.int/medicinedocs/documents/s16879e/s16879e.pdf|accessdate=8 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161213060118/http://apps.who.int/medicinedocs/documents/s16879e/s16879e.pdf|archivedate=13 December 2016|df=}}</ref> It is used by [[intramuscular|injection into a muscle]], [[intravenous|vein]], or [[Subcutaneous injection|under the skin]].<ref name=AHFS2016/>

<!-- Side effects and mechanism -->
Common side effects include pain at the site of injection, diarrhea, vomiting, fever, [[hearing loss]], and eye problems.<ref name=AHFS2016/> Severe [[allergic reactions]] including [[anaphylaxis]] and [[low blood pressure]] may occur.<ref name=AHFS2016/> It is unclear if use during [[pregnancy]] or [[breastfeeding]] is safe for the baby.<ref>{{cite web|title=Deferoxamine (Desferal) Use During Pregnancy|url=https://www.drugs.com/pregnancy/deferoxamine.html|website=www.drugs.com|accessdate=13 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161221002833/https://www.drugs.com/pregnancy/deferoxamine.html|archivedate=21 December 2016|df=}}</ref> Deferoxamine is a [[siderophore]] from the bacteria ''[[Streptomyces pilosus]]''.<ref>{{cite book|last1=Hoffman|first1=Ronald|last2=Jr|first2=Edward J. Benz|last3=Silberstein|first3=Leslie E.|last4=Heslop|first4=Helen|last5=Weitz|first5=Jeffrey|last6=Anastasi|first6=John|title=Hematology: Diagnosis and Treatment|date=2012|publisher=Elsevier Health Sciences|isbn=1-4557-4041-1|page=515|edition=6|url=https://books.google.ca/books?id=M5fD7gZSDYMC&pg=PA515|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20161220111527/https://books.google.ca/books?id=M5fD7gZSDYMC&pg=PA515|archivedate=2016-12-20|df=}}</ref>

<!-- History and culture -->
Deferoxamine was approved for medical use in the United States in 1968.<ref name=AHFS2016>{{cite web|title=Deferoxamine Mesylate|url=https://www.drugs.com/monograph/deferoxamine-mesylate.html|publisher=The American Society of Health-System Pharmacists|accessdate=8 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161221002616/https://www.drugs.com/monograph/deferoxamine-mesylate.html|archivedate=21 December 2016|df=}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref> The wholesale cost in the [[developing world]] is about 6.76 to 13.52 USD per dose.<ref name=ERC2014>{{cite web|title=Deferoxamine|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=DEF500A&s_year=2014&year=2014&str=500%20mg&desc=Deferoxamine%20Mesilate&pack=new&frm=AMPOULE&rte=INJ&class_code2=&supplement=&class_name=%2804%2E2%2E%29Specific%20antidotes%3Cbr%3E%28%29%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=8 December 2016}}</ref> In the United States a course of treatment costs more than 200 USD.<ref name=Ric2015>{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=978-1-284-05756-0|page=470}}</ref>

==Medical uses==
Deferoxamine is used to treat acute [[iron poisoning]], especially in small children. This agent is also frequently used to treat [[hemochromatosis]], a disease of iron accumulation that can be either genetic or acquired. Acquired hemochromatosis is common in patients with certain types of chronic [[anemia]] (e.g. [[thalassemia]] and [[myelodysplastic syndrome]]) who require many [[blood transfusion]]s, which can greatly increase the amount of iron in the body. Administration for chronic conditions is generally accomplished by [[subcutaneous injection]] over a period of 8–12 hours each day. Administration of deferoxamine after acute intoxication may color the urine a pinkish red, a phenomenon termed "''vin rosé'' urine".

Apart from iron toxicity, deferoxamine can be used to treat [[aluminium]] toxicity (an excess of aluminium in the body) in select patients. In US, the drug is not FDA-approved for this use.

Deferoxamine is also used to minimize [[doxorubicin]]'s cardiotoxic side effects and in the treatment of a patient with [[aceruloplasminemia]].<ref name="acerulo1">{{cite journal |doi=10.1002/ana.410410318 |pmid=9066364 |title=Use of desferrioxamine in the treatment of aceruloplasminemia |journal=Annals of Neurology |volume=41 |issue=3 |pages=404–7 |year=1997 |last1=Miyajima |first1=Hiroaki |last2=Takahashi |first2=Yoshitomo |last3=Kamata |first3=Tadashi |last4=Shimizu |first4=Hideaki |last5=Sakai |first5=Naoki |last6=Gitlin |first6=Jonathan D. }}</ref>

==Mechanism==
Deferoxamine acts by binding free iron in the bloodstream and enhancing its elimination in the [[urine]]. By removing excess iron, the agent reduces the damage done to various organs and tissues, such as the [[liver]]. Also, it speeds healing of nerve damage (and minimizes the extent of recent nerve trauma).{{Citation needed|reason=A citation is needed for the claim that a recent study has shown DFO to speed nerve regeneration|date=August 2013}} Deferoxamine may modulate expression<ref>{{cite journal |doi=10.1186/1471-2407-7-176 |pmid=17850672 |pmc=2078595 |title=Differential regulation of iron chelator-induced IL-8 synthesis via MAP kinase and NF-κB in immortalized and malignant oral keratinocytes |journal=BMC Cancer |volume=7 |pages=176 |year=2007 |last1=Lee |first1=Hwa-Jeong |last2=Lee |first2=Jun |last3=Lee |first3=Sun-Kyung |last4=Lee |first4=Suk-Keun |last5=Kim |first5=Eun-Cheol }}</ref> and release of inflammatory mediators by specific cell types.<ref>{{cite journal |pmid=15153529 |url=http://www.jimmunol.org/cgi/pmidlookup?view=long&pmid=15153529 |year=2004 |author1=Choi |first1=E. Y. |title=Iron chelator triggers inflammatory signals in human intestinal epithelial cells: Involvement of p38 and extracellular signal-regulated kinase signaling pathways |journal=Journal of Immunology |volume=172 |issue=11 |pages=7069–77 |last2=Kim |first2=E. C. |last3=Oh |first3=H. M. |last4=Kim |first4=S |last5=Lee |first5=H. J. |last6=Cho |first6=E. Y. |last7=Yoon |first7=K. H. |last8=Kim |first8=E. A. |last9=Han |first9=W. C. |last10=Choi |first10=S. C. |last11=Hwang |first11=J. Y. |last12=Park |first12=C |last13=Oh |first13=B. S. |last14=Kim |first14=Y |last15=Kimm |first15=K. C. |last16=Park |first16=K. I. |last17=Chung |first17=H. T. |last18=Jun |first18=C. D. }}</ref>

==Research==
Deferoxamine is being studied as a treatment for spinal cord injury<ref>http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000120.jsp&mid=WC0b01ac058001d12b {{webarchive|url=https://web.archive.org/web/20130717223511/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Fhuman%2Forphans%2F2009%2F11%2Fhuman_orphan_000120.jsp&mid=WC0b01ac058001d12b |date=2013-07-17 }}{{full citation needed|date=February 2017}}</ref> and intracerebral hemorrhage.<ref name="pmid21102602">{{cite journal |doi=10.1038/jcbfm.2010.209 |pmid=21102602 |pmc=3099628 |title=Iron toxicity in mice with collagenase-induced intracerebral hemorrhage |journal=Journal of Cerebral Blood Flow & Metabolism |volume=31 |issue=5 |pages=1243–50 |year=2010 |last1=Wu |first1=He |last2=Wu |first2=Tao |last3=Xu |first3=Xueying |last4=Wang |first4=Jessica |last5=Wang |first5=Jian }}</ref> It is also used to induce hypoxia-like environment in mesenchymal stem cells.<ref>{{cite journal |doi=10.1016/j.bbrc.2006.05.169 |pmid=16814746 |title=Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions |journal=Biochemical and Biophysical Research Communications |volume=347 |issue=1 |pages=12–21 |year=2006 |last1=Ren |first1=Hongying |last2=Cao |first2=Ying |last3=Zhao |first3=Qinjun |last4=Li |first4=Jing |last5=Zhou |first5=Cixiang |last6=Liao |first6=Lianming |last7=Jia |first7=Mingyue |last8=Zhao |first8=Qian |last9=Cai |first9=Huiguo |last10=Han |first10=Zhong Chao |last11=Yang |first11=Renchi |last12=Chen |first12=Guoqiang |last13=Zhao |first13=Robert Chunhua }}</ref><ref>{{cite journal |doi=10.1016/j.bbrc.2006.02.116 |pmid=16527254 |title=Desferrioxamine, an iron chelator, enhances HIF-1α accumulation via cyclooxygenase-2 signaling pathway |journal=Biochemical and Biophysical Research Communications |volume=343 |issue=1 |pages=8–14 |year=2006 |last1=Woo |first1=Kyung Jin |last2=Lee |first2=Tae-Jin |last3=Park |first3=Jong-Wook |last4=Kwon |first4=Taeg Kyu }}</ref>

==See also==
*[[Chelation therapy]]

==References==
{{reflist|32em}}

{{chelating agents}}

[[Category:Siderophores]]
[[Category:Antidotes]]
[[Category:Hydroxamic acids]]
[[Category:World Health Organization essential medicines]]
[[Category:Amines]]
[[Category:Carboxamides]]
[[Category:Chelating agents]]
[[Category:Chelating agents used as drugs]]
[[Category:RTT]]